Purpose: To assess the amide proton transfer-weighted (APTw) MRI features of isocitrate dehydrogenase (IDH)-wildtype and IDH-mutant grade II gliomas and to test the hypothesis that the APTw signal is a surrogate imaging marker for identifying IDH mutation status preoperatively. Methods: Twenty-seven patients with pathologically confirmed low-grade glioma, who were previously scanned at 3T, were retrospectively analyzed. The Mann-Whitney test was used to evaluate relationships between APTw intensities for IDHmutant and IDH-wildtype groups, and receiver operator characteristic (ROC) analysis was used to assess the diagnostic performance of APTw. Results: Based on histopathology and molecular analysis, seven cases were diagnosed as IDH-wildtype grade II gliomas and 20 cases as IDH-mutant grade II gliomas. The maximum and minimum APTw values, based on multiple regions of interest, as well as the whole-tumor histogram-based mean and 50th percentile APTw values, were significantly higher in the IDH-wildtype gliomas than in the IDH-mutant groups. This corresponded to the areas under the ROC curves of 0.89, 0.76, 0.75, and 0.75, respectively, for the prediction of the IDH mutation status. Conclusion: IDH-wildtype lesions typically were associated with relatively high APTw signal intensities as compared with IDHmutant lesions. The APTw signal could be a valuable imaging biomarker by which to identify IDH1 mutation status in grade II gliomas.
INTRODUCTION
Gliomas are the most common primary brain tumors, and more than 23,770 new cases are diagnosed in the United States each year (1) . The recent breakthrough in the understanding of isocitrate dehydrogenase (IDH) mutations in glioma has resulted in a prompt reappraisal of the molecular oncogenesis of this group of diseases (2) (3) (4) (5) . Notably, for the first time the most recent 2016 World Health Organization (WHO) classification of central nervous system (CNS) tumors uses molecular parameters, in addition to histology, to define tumor entities, thus formulating a basis for how CNS tumor diagnoses should be structured in the molecular era (6) . The IDH enzyme catalyzes the oxidative decarboxylation of isocitrate to a-ketoglutarate, which is needed for producing reduced nicotinamide adenine dinucleotide and reduced nicotinamide adenine dinucleotide phosphate during cellular respiration. Mutations in IDH genes, which occur in the majority of WHO grade II and III gliomas and secondary glioblastomas, have been postulated to indicate a favorable clinical prognosis (2) (3) (4) (5) . Because IDH geneencoded enzymes are closely involved in the energyproducing Krebs cycle as catalytic isozymes, mutations in IDH genes may cause widespread disturbances of cellular metabolism, including alteration of amino acid concentrations and enzymatic activity (7, 8) , and raise global DNA hypermethylation and global downregulation of protein expression as well (9, 10) . Therefore, IDH-directed therapy, including IDH inhibitors and DNA methyltransferase inhibitors, have been developed and may impart a cumulative clinical benefit for the targeted patients (11) .
As popularly applied in clinical practice, IDH mutation screening generally is performed with an immunohistochemical (IHC) assay on surgical samples using antibodies that detect IDH1-R132H. More than 85% of all genetic alterations in IDH1 in gliomas are heterozygous missense mutations of arginine to histidine (R132H); thus, this immunohistochemical approach will detect the majority of cases (12) . For IHC-negative or IHC-equivocal cases, DNA sequencing is recommended as a complementary test (13) .
However, it is not uncommon that lab tests lead to falsenegative results when inadequate neoplastic cells from a biopsy procedure are mixed in with the normal cell background. Thus, sufficient tumor tissue should be obtained from surgery, while balancing the benefits of removing tumor versus the potential risks for damaging normal tissue in patients with low-grade gliomas. It is these aspects of IDHwildtype and IDH1-mutant gliomas that provide impetus for the preoperative determination of IDH mutational status, with methods such as MRI, which potentially can rapidly and noninvasively provide a comprehensive assessment. Such imaging methods could at minimum be used to better guide the biopsies needed for ICH assessment.
In recent years, researchers have evaluated the feasibility of applying several MRI techniques to determine IDH status in patients with gliomas (14) (15) (16) (17) (18) , including gadoliniumenhanced T 1 -weighted (Gd-T 1 w) images (19) , diffusion (20) (21) (22) , perfusion (23) , sodium MRI (24) , and machinelearning algorithms (25, 26) . Notably, because lab studies have proven that the oncometabolite 2-hydroxyglutarate (2-HG) holds a 100-fold increase in IDH-mutant cells compared to IDH-wildtype type cells (27) , recent studies also have shown that significantly higher 2-HG detected by single-voxel MRS can identify patients with IDH1-mutant gliomas with high sensitivity (28) (29) (30) . However, the MRS detection of 2-HG in IDH-mutant gliomas requires a large tumor volume (31) and is time-consuming, which limits the application of MRS. In addition, partial volume effects between different tumor regions may obscure the presence of 2-HG in smaller regions.
Amide proton transfer-weighted (APTw) MRI, a specific type of chemical exchange-dependent saturation transfer (CEST) imaging (32, 33) is an upcoming molecular imaging technique that can generate image contrast based on the endogenous cellular mobile proteins in tissue (34, 35) . Since APT imaging was first reported in 2003 (34, 35) , it has been studied as an imaging biomarker in a variety of cancers (36) (37) (38) (39) (40) (41) and nononcologic diseases (42) (43) (44) (45) . For glial neoplasms in particular, consistent APTw MRI results have been produced across various labs, showing promise for the grading of gliomas (distinct hyperintensity in grades III and IV gliomas vs. isointensity to minimal hyperintensity in grade II gliomas) (46) (47) (48) , which demonstrate increasing protein concentrations with grade, as revealed by proteomics (49, 50) and in vivo MR spectroscopy (51) . In this study, we assessed the APTw MRI features for IDH-wildtype and IDH-mutant grade II gliomas before surgery, with the hypothesis that APTw signal intensity metrics could aid in the preoperative identification of the IDH genotype in grade II gliomas.
METHODS

Patients
This retrospective study was approved by the local institutional review board, and informed consent was waived. Enrollment criteria were as follows: ! 18 years old; APTw and routine MRI scanning occurred within 7 days preoperatively; histopathologically confirmed as a WHO grade II astrocytoma, oligoastrocytoma, or oligodendroglioma (according to their medical records; originally based on the 2007 WHO criteria); IDH1 mutation status and 1p/19q codeletion status available from operative sample; and received no radiotherapy or chemotherapy before imaging. Exclusion criteria included inferior image quality due to various reasons.
MRI Data Acquisition
MRI scanning was performed on a 3T clinical MRI scanner (Achieva; Philips Medical Systems, Best, The Netherlands). Amide proton transfer image data were obtained with a fatsuppressed, single-shot, fast spin-echo pulse sequence using the following parameters: radiofrequency saturation power-¼ 2 mT, duration ¼ 800 ms (four block pulses, 200 ms each; interpulse delay, 10 ms); repetition time ¼ 3 s, echo time ¼ 11 ms, matrix ¼ 140 Â 70 (reconstructed to be 400 Â 400), sensitivity-encoding factor ¼ 2, turbo spin-echo factor ¼ 37, field of view ¼ 240 Â 240 mm 2 , and slice thickness ¼ 6 mm. A single-slice, combined APTw imaging and Z-spectrum acquisition protocol (31 offsets ¼ 0, 6 0.25, 6 0.5, 6 0.75, 6 ¼ 0, 6 0.25, 6 0.5, 6 0.75, 6 1, 6 1.5, 6 2, 6 2.5, 6 3 (2), 6 3.25 (4), 6 3.5 (8), 6 3.75 (4), 6 4 (2), 6 4.5, 6 5, 6 6 ppm; the values in parentheses were the number of acquisitions, which was 1, if not specified) was applied to the maximum cross-sectional tumor area (as determined by standard MRI images). More acquisitions were obtained at and around 63.5 ppm to obtain a sufficient signal-to-noise ratio for APTw images. More offsets were used near 0 ppm to increase the fitting accuracy of B 0 maps, and more offsets were used close to 63.5 ppm to increase the interpolation accuracy of APTw data for B 0 correction (36) . A saturated image at 15.6 ppm (or 2 kHz at 3T) also was acquired to calculate magnetization transfer ratio (MTR) values for conventional semisolid magnetization transfer (MT) imaging. The scanning time for this combined scan was about 3 minutes. Several standard MRI sequences were acquired for reference, including T 2 -weighted (T 2 w), T 1 w, and Gd-T 1 w. The Gd-T 1 w imaging (0.2 mL/kg body weight; Magnevist, Bayer Schering, Guangzhou, China) was the last sequence acquired.
APTw and MT Image Processing
The image analysis was performed by the interactive data language (IDL 7; Exelis Visual Information Solutions, Inc., Boulder, Colorado, USA). To reduce possible motion artifacts during the scanning, the acquired APTw image or Zspectrum series was registered to the saturated image at 3.5 parts per million (ppm) (52) . The acquired APTw image or Z-spectrum series was further corrected for the B 0 inhomogeneity effect on a voxel-by-voxel basis, as previously described (36) . The APTw image was constructed with the so-called magnetization transfer-ratio asymmetry at the offsets of 63.5 ppm (34,35): MTR asym (3.5 ppm) ¼ S sat (À3.5 ppm)/S 0 À S sat (þ3.5 ppm)/S 0 , in which S sat and S 0 are the imaging signal intensities with and without selective radiofrequency irradiation, respectively. To account for the contribution of the possible nuclear Overhauser enhancement (NOE) effect of protons in mobile and relatively mobile proteins at À3.5 ppm on MTR asym (3.5 ppm) (53) (54) (55) (56) , as well as possible asymmetries in the conventional semisolid-based MT effect (57), the calculated MTR asym (3.5 ppm) image is best described as the APTw image (46) . In addition, for conventional MT imaging, MTR (2 kHz) ¼ 1 À S sat (2 kHz)/S 0 .
APTw and MT Image Analysis
To perform quantitative APTw and MTR analyses, the acquired conventional MR images from each case were coregistered to the corresponding saturated S sat image at 3.5 ppm, which was coregistered with the APTw image, as described previously (52) . Primarily based on the T 2 w image, regions of interest (ROIs) were carefully drawn by radiologists (S.J. and x.W., with 10 and 7 years of experience in brain imaging, respectively), together with MRI physicists. One large ROI covering the whole area of abnormal intensity on the T 2 w image was first drawn. Similar to some previous reports (38, 39) , five small tumor ROIs were further chosen in the T 2 w-hyperintense lesion area. Each ROI encompassed approximately 100 to 130 voxels (reconstructed). ROIs excluded the large cyst, hemorrhage, or vessels evident on standard MRI sequences. The contralateral normal-appearing white matter (CNAWM) also was analyzed, and relative APTw values were reported (ROI APTw-CNAWM APTw). For each case, the maximum and minimum APTw values among the five small tumor ROIs, as well as the Z-spectrum data and APTw histogram data corresponding to the ROI with maximum APTw (tumor core), were recorded. For the large whole-tumor ROI, the Z-spectrum data, APTw histogram data, and average MTR value were recorded. The histogram data were analyzed for mean, variance, skewness, kurtosis, slope, 10th percentile, 50th percentile, 90th percentile, and peak values, as defined before (58) .
Histopathological Evaluation
Operative tissue samples were processed using standard clinical techniques. IDH1-R132H evaluation was performed by IHC and DNA sequencing, as described previously (13, 59) . Paraffin-embedded slices of operative specimens were stained with IDH1-R132H-specific antibody (1:50; H09 clone; Dianova, Hamburg, Germany). To amplify exon 4 (codon R132) of the IDH1 gene, we designed the forward primer (5 0 -ACC AAA TGG CAC CAT ACG A-3 0 ) and reverse primer (5 0 -GCA AAA TCA CAT TAT TGC CAA C-3 0 ). Fluorescent in situ hybridization testing was applied to assess the 1p/19q codeletion.
An experienced pathologist (Y.W.), blinded to the imaging findings, evaluated and reclassified all the cases according to the 2016 WHO classification of central nervous system tumors (6) . Tumor grading documented in the clinical pathological reports (originally based on 2007 WHO criteria and reported by multiple pathologists) was confirmed for all patients enrolled. The molecular pathological reports (IDH, 1p/19q) were taken into account.
Statistical Analysis
The data were reported as means and standard deviations. After normality testing, the Mann-Whitney U test was used to analyze the statistical differences between quantitative imaging parameters for the two IDH mutation statuses. We further employed receiver operating characteristic curve (ROC) analysis to assess the diagnostic performance of APTw metrics. All statistical analyses were performed using statistical software (SPSS 23; Chicago, Illinois, USA). Generated P values were two-tailed, and P < 0.05 was considered statistically significant.
RESULTS
Patient Demographics
Between 2014 and 2016, 31 patients who fulfilled the eligibility criteria according to their medical records were retrospectively analyzed. Patients typically showed some neurological deficit or seizures. Twenty-seven patients (15 males, 12 females) were finally recruited for this study after four patients were excluded (inferior image quality duo to the patient movement, n ¼ 3; or irremovable artifacts caused by a large intratumoral hemorrhage, n ¼ 1). The clinical characteristics of the patient population are summarized in Table 1 . Tissue samples were available from all subjects either by stereotactic biopsy (n ¼ 3); gross total resection (n ¼ 21); or subtotal resection (n ¼ 3). IDH mutations were found in 20 cases (74.1%), 15 of which were histopathologically classified as oligodendrogliomas, IDH-mutant, and 1p/19q codeleted, and five as diffuse astrocytomas, IDH-mutant. In the seven patients (25.9%) with IDH-wildtype glioma, all were classified as diffuse astrocytomas, IDH-wildtype.
Comparison Between MTR asym Spectra for IDH-Wildtype and IDH-Mutant Gliomas
The average MTR asym spectra for the groups of patients with IDH-wildtype and IDH-mutant gliomas were compared to explore the specific characteristics of the APT effect at an offset of $3.5 ppm downfield from water ( Fig. 1) . Both glioma types demonstrated stronger protein-based APT and other CEST effects in the offset range of 1.5 to 4 ppm, compared to CNAWM. As reported previously (46) , all MTR asym spectra were negative at the higher frequency ( > 4.5 ppm) due to the upfield NOE effect and the conventional MT asymmetry. The CEST signal intensities in the offset range of 1.5 to 4 ppm (including the APT signal at 3.5 ppm downfield from water) were relatively higher in IDH-wildtype than in IDH-mutant gliomas, except for the CEST effect at 2.0 ppm (35, 60) , which showed no difference in absolute MTR asym between the two glioma types but stood out in intensity relative to the other frequencies in the mutant type. Particularly in the IDH-wildtype tumor core, a relatively high APT effect was clearly observed at 3.5 ppm offset from water, at which the amide protons of endogenous mobile proteins and peptides resonate (61) . The APTw-MRI metrics are associated with relevant proteomic characteristics that may provide valuable information for the noninvasive discrimination of IDH mutation status.
Comparison Between APTw Images for IDH-Wildtype and IDH-Mutant Gliomas
The APTw features of the IDH-wildtype and IDH-mutant gliomas (WHO grade II) were further accessed using several standard MRI (T 2 w, T 1 w, and Gd-T 1 w) sequences. Of seven IDH-wildtype gliomas (WHO grade II), four lesions were located in the temporal lobe, and the remaining three lesions were mainly involved in the frontotemporal lobe. Figure 2 shows one example of standard and APTw MR images for an IDH-wildtype glioma (WHO grade II). All seven lesions showed no visible enhancement on the postcontrast T 1 w images. The APTw images showed mildly increased hyperintensity in T 2 w-hyperintense areas (at least some portions), compared to the CNAWM, demonstrating the IDH-wildtype lesions as relatively heterogeneous masses with scattered punctate or pitchy, high APTw signals.
Of 20 patients with IDH-mutant gliomas (WHO grade II), 11 had lesions located in the frontal lobe, five had lesions located in the temporal lobe, and five had the major lesion located in the frontotemporal lobe. Figure 3 shows one example of the standard and APTw MR images for a patient with an IDH-mutant oligodendroglioma. These IDH-mutant gliomas showed no (n ¼ 19) or slightly central faint (n ¼ 1) enhancement on the postcontrast T 1 w images. All lesions showed visually homogeneous isointensity to minimal APTw hyperintensity in T 2 w-hyperintense areas, compared to the CNAWM. Figure 4 shows histograms of APTw values obtained from whole tumor, tumor core (corresponding to the ROI with maximum APTw), and CNAWM for IDH-wildtype and IDH-mutant grade II gliomas. The multi-ROI-based (maximum and minimum) and whole-tumor histogrambased (mean, variance, skewness, kurtosis, slop, 10th percentile, 50th percentile, 90th percentile, and peak) APTw metrics for IDH-wildtype and IDH-mutant gliomas, together with the MTR value, are summarized in Table 2 . Differences between APTw values for IDHwildtype and IDH-mutant gliomas, based on histogram analysis that corresponded to the ROI with maximum APTw, are summarized in Supporting Table S1 . FIG. 1. (a,b) Comparison of the average MTR asym spectra of whole tumor, tumor core, and CNAWM for IDH-wildtype (a) and IDHmutant (b) grade II gliomas. The CEST effects were clearly visible at multiple frequencies in the frequency offset range to 1.5-4 ppm. (c,d) MTR asym spectra relative to CNAWM providing the relative APTw intensities. The most significant CEST effect was the APT at 3.5 ppm in the IDH-wildtype tumor core.APTw, amide proton transfer-weighted; CNAWM, contralateral normal-appearing white matter; IDH, isocitrate dehydrogenase; MTR, magnetization transfer ratio.
Quantitative APTw and MTR Analyses
Predicting IDH Status With APTw MRI
Based on the multi-ROI analysis, the IDH-wildtype gliomas had higher maximum (2.03 6 0.72 vs. 0.99 6 0.33) and minimum (0.99 6 0.47 vs. 0.59 6 0.32) APTw values than the IDH-mutant gliomas, both of which were statistically significant (P < 0.001 and P ¼ 0.02, respectively). Based on the histogram-based analysis, the IDH-wildtype gliomas had significantly higher mean (1.39 6 0.49 vs. 0.93 6 0.44; P ¼ 0.03) and 50th percentile (1.39 6 0.46 vs. 0.96 6 0.36; P ¼ 0.02) APTw values than the IDH-mutant group. Three other histogram parameters, 10th percentile, 90th percentile, and peak values, showed a higher trend in the IDH-wildtype group compared to the IDHmutant group (P ¼ 0.06-0.18; insignificantly). For variance, skewness, kurtosis, and slope of APTw values, there were no significant differences between the two glioma groups (P > 0.2). Further, the whole-tumor MTR values showed no significant difference between the IDH-wildtype and IDH-mutant groups (14.9 6 2.1 vs. 16.3 6 2.5.3; P ¼ 0.63).
Prediction of IDH Mutation With APTw Metrics
Among 11 APTw metrics, the multi-ROI-based maximum and minimum APTw values, as well as the histogrambased mean and 50th percentile APTw values, differed significantly between the IDH-wildtype and IDH-mutant groups. Based on ROC curve analyses (Supporting Fig.  S1 ), the multi-ROI-based maximum values showed the highest area under the ROC curve (0.89); and the areas under the ROC curves for the multi-ROI-based minimum, histogram-based mean, and histogram-based 50th percentile APTw metrics in predicting the IDH mutation status were 0.76, 0.75, and 0.75, respectively (Table 3) . IDH mutation status thus was predictable with APTw imaging, noninvasively.
DISCUSSION
Low-grade gliomas yield widely different clinical outcomes. The modernized understanding of the somatic mutations of the IDH 1 and 2 genes in gliomas allows us to better subclassify this group of entities that have distinguished prognosis, opening up a new era in the treatment of brain tumors. In spite of the frequency of IDHwildtype is relatively rare in the population with WHO grade II gliomas, around 20% (62), IDH-wildtype gliomas are prone to have poorer prognosis (63) . Thus, predicting the IDH-mutant status preoperatively, preferably with noninvasive imaging modalities, has become a focus of the oncology community. Although promising, most previous studies have been experimental, and thus far results have been mixed, which has hampered consistent clinical application. Therefore, most clinicians agree that more specific imaging modalities are urgently needed to help distinguish IDH-wildtype from IDH-mutant gliomas, especially in ambiguous cases for which biopsy could potentially be avoided. CEST imaging provides an important contrast mechanism for molecular MRI (32, 33) , and this study is the first to evaluate the ability of CEST-MRI to discriminate IDH-wildtype and IDH-mutant low-grade gliomas preoperatively. Based on the entire MTR asym spectra (Fig. 1) , we found that the CEST signal intensities in the offset range of 1.5 to 4 ppm (including the protein-based APTw signal at 3.5 ppm downfield from water) were relatively higher in IDH-wildtype than in IDH-mutant grade II gliomas, except for the CEST effect at 2.0 ppm, which showed no difference between the two glioma types. Interestingly, IDH-mutant gliomas showed an obviously decreased CEST effect at 2.5 ppm, in addition to 3.5 ppm (APT effect), compared to IDH-wildtype gliomas. The exact mechanism for it needs to be further explored in the future.
In this study, we applied two ROI drawing approaches for APTw value analysis: 1) histogram analysis and 2) multi-ROI-based analysis, and then multiple APTw metrics were obtained. Both APTw analysis methods are able to yield discriminated indexes. Generally, histogram analysis has priority over multi-ROI-based analysis in terms of the operation simplicity because the latter should be used with caution by excluding large cysts, hemorrhage, or vessels. However, multi-ROI-based analysis is useful for finding tumor hotspots. We found that multi-ROI-based maximum and minimum APTw values, as well as the histogram-based mean and 50th percentile APTw values, were significantly higher in IDH-wildtype gliomas than in IDH-mutant gliomas (Table 2) , corresponding to areas under the ROC curves of 0.89, 0.76, 0.75, and 0.75, respectively, for the prediction of the IDH mutation status (Table 3) . Although the APTw difference between IDH-wildtype and IDH-mutant was very small, it was enough to help making discrimination, showing moderate areas under the ROC curves for these APTw metrics. Therefore, the APTw signal could be a valuable imaging biomarker with which to identify IDH1 mutation status in grade II gliomas.
According to the CEST theory (64), APTw imaging can generate contrast that to a large extent depends on the concentration of endogenous cellular proteins in tissue and the exchange properties of their amide protons with water protons (pH-dependent), whereas other parameters (tissue water content, T 1 of water, saturation efficiency) affect the contrast. However, it is imperative to realize that the effect of an increasing water T 1 on the measured APTw signal is mostly canceled out by the effect of the Predicting IDH Status With APTw MRIincreasing water content in the tumor (34, 65) . Our further results (66) have shown that it may not be necessary to correct for the influence of water T 1 on APT imaging of gliomas, at least at 2 mT, as was used in this study, although this remains an interesting research topic in the field. Based on previous 31 P NMR spectroscopy studies in experimental brain tumors and in patients with brain tumors (67, 68) , the intracellular pH of untreated malignant gliomas was near neutrality, or a little alkaline (with a slight increase of 0.05À0.08 pH unit reported in the literature). Thus, the observed APT effect in tumor mostly is dominated by the increased amide proton concentration related to mobile cellular proteins (e.g., cytosolic proteins, many endoplasmic reticulum proteins, and secreted proteins) (69) ; however, an extra contribution from the possibly alkaline intracellular pH may exist, as discussed in our early papers (65) . Notably, lab research results have shown global downregulation of protein expression in mutant IDH1-driven glioma cells, compared to oncogenic HRAS IDH1-wildtype glioma cells (10) , which is consistent with our findings that significantly lower APTw signal intensities were observed in IDH-mutant grade II gliomas. Conventional MT imaging generates unique contrast in MRI that is related to semisolid macromolecules, such as those in membranes and nuclei (70) . Our research did not find any significant difference in MTR between IDH-mutant and IDHwildtype grade II gliomas, suggesting a negligible difference in the more solid environment of the cell for these two tumor types. In addition, our results in this study are consistent with a recent study by Xiong et al. (22) , who reported that IDH mutations significantly correlated with a lower cell proliferation in grade II oligodendroglial tumors, thus leading to a lower APTw signal. There are some limitations or weaknesses in this study. A limitation of our study was the relatively small sample size, especially for the numbers in the IDH-wildtype group due to the inherent IDH mutation distribution ratio in the general population (63) . A large-scale study would be required to obtain more conclusive results. Another limitation was that different experimental saturation settings will give different results; the contrast needs to be standardized. The final potential limitation was the semiquantitative characteristic of APTw signal intensity. This signifies that the APTw intensity has multiple contributions, including the upfield NOE effect (53-56) and some conventional semisolid MT asymmetry, which are mixed in when performing MTR asym analysis. Fortunately, our recent studies showed that for the saturation parameters we used, the APT effect (rather than the NOE) would be the major contributor to the APTw image contrast between the tumor and normal brain tissue (or the relative APTw intensity value in the tumor, compared to normal brain tissue, as used in this study) (54, 65, 71) . Thus, we believe that our results would be very close to those based on the absolute quantitative APT metrics. Several alternative APTw imaging analysis or acquisition approaches have been proposed to quantify a pure APT effect (72) (73) (74) (75) . Notably, the extrapolated semisolid magnetization transfer reference model that is being developed by our group (71) should achieve a purer APT quantification. We will apply this promising imaging analysis method to our future research.
CONCLUSION
The present study represents the first analysis of the ability to use APTw MRI to differentiate between IDH-wildtype and IDH-mutant grade II gliomas. IDH mutation status is associated with distinct APTw signatures, and IDH1-wildtype lesions typically are correlated with relatively high APTw signal intensities as compared with IDH1-mutant lesions. Our early results highlight the potential future of APTw imaging to provide a more precise genotypic diagnostic workup of gliomas. Noninvasive prediction of IDH1 mutation status could provide more valuable supplementary information about the prognosis of grade II gliomas before surgery. 
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